A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
for
Peritoneal Carcinomatosis, Ovarian Cancer
Location: Tampa FL
Sponsor: Oncoinvent Solutions AS
Sex: Female
Age: 18+
Code: NCT06504147
Phase2, Recruiting
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
for
Ovarian Cancer Recurrent
Location: Boston MA, New Haven CT, New York NY, Montreal,
Sponsor: Merck Sharp & Dohme LLC
Sex: Female
Age: 18+
Code: NCT06843447
Phase1, Phase2, Recruiting
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
for
Ovarian Cancer, Epithelial Ovarian Cancer,
Location: Kansas City KS
Sponsor: Andrea Jewell
Sex: Female
Age: 18+
Code: NCT03321188
Phase2, Recruiting
Lead-212 PSV359 Therapy for Patients With Solid Tumors
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
for
Platinum-resistant Ovarian Cancer
Location: Newport Beach CA, El Segundo CA
Sponsor: ImmunityBio, Inc.
Sex: Female
Age: 18 - 70+
Code: NCT06710288
Phase2, Recruiting
13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
for
Ovarian Cancer, Ascites
Location: Victoria
Sponsor: British Columbia Cancer Agency
Sex: Female
Age: 18+
Code: NCT05025878
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
for
Ovarian Cancer
Location: Boston MA, New York NY, Paramus NJ, Bethlehem PA,
Sponsor: Daiichi Sankyo
Sex: Female
Age: 18+
Code: NCT06819007
Phase3, Recruiting
CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
for
Recurrent Ovarian Cancer
Location: Pittsburgh PA
Sponsor: Lan Coffman
Sex: Female
Age: 18+
Code: NCT05942300
Phase1, Recruiting
An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study